(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.62%) $79.49
(1.24%) $1.956
(0.78%) $2 329.10
(0.29%) $26.83
(1.34%) $967.70
(0.01%) $0.933
(-0.03%) $11.03
(-0.08%) $0.798
(0.27%) $93.51
-0.25% £ 976.60
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
Volumen de hoy | 3.78M |
Volumen promedio | 3.66M |
Capitalización de mercado | 8.54B |
EPS | £0 ( 2024-05-01 ) |
Last Dividend | £18.38 ( 2023-03-30 ) |
Next Dividend | £0 ( N/A ) |
P/E | 40.69 |
ATR14 | £0.953 (0.10%) |
Volumen Correlación
Smith & Nephew plc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Smith & Nephew plc Correlación - Moneda/Commodity
Smith & Nephew plc Finanzas
Annual | 2023 |
Ingresos: | £5.55B |
Beneficio Bruto: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2023 |
Ingresos: | £5.55B |
Beneficio Bruto: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2022 |
Ingresos: | £5.22B |
Beneficio Bruto: | £3.68B (70.47 %) |
EPS: | £0.250 |
FY | 2021 |
Ingresos: | £5.21B |
Beneficio Bruto: | £3.67B (70.40 %) |
EPS: | £0.598 |
Financial Reports:
No articles found.
Smith & Nephew plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£12.91 (N/A) |
£0 (N/A) |
£18.38 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £3.45 | 1993-05-10 |
Last Dividend | £18.38 | 2023-03-30 |
Next Dividend | £0 | N/A |
Payout Date | 2023-05-17 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | £440.59 | -- |
Avg. Dividend % Per Year | 1.26% | -- |
Score | 4.16 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 4.99 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
1993 | £0 | 0.00% |
1994 | £0 | 0.00% |
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £26.91 | 1.93% |
2019 | £28.49 | 1.99% |
2020 | £29.73 | 1.62% |
2021 | £27.12 | 1.73% |
2022 | £31.31 | 2.40% |
2023 | £18.38 | 1.64% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TFIF.L | Dividend Knight | 2023-07-20 | Quarterly | 12 | 4.62% | |
LIT.L | Ex Dividend Knight | 2023-09-28 | Sporadic | 6 | 0.00% | |
CLIG.L | Dividend King | 2023-09-28 | Semi-Annually | 18 | 3.51% | |
RHIM.L | Dividend Knight | 2023-08-24 | Annually | 7 | 3.49% | |
HAT.L | Dividend Knight | 2023-09-07 | Semi-Annually | 18 | 2.55% | |
ASL.L | Dividend Knight | 2023-08-03 | Semi-Annually | 34 | 1.34% | |
UKCM.L | Dividend King | 2023-08-17 | Quarterly | 18 | 2.99% | |
MIG5.L | Dividend Knight | 2023-06-22 | Semi-Annually | 24 | 4.45% | |
D4T4.L | Dividend Knight | 2023-07-20 | Semi-Annually | 27 | 1.32% | |
SEIT.L | Dividend Knight | 2023-09-14 | Quarterly | 6 | 3.23% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0474 | 1.500 | 9.05 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0263 | 1.200 | 9.12 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0503 | 1.500 | -0.552 | -0.828 | [0.1 - 1] |
payoutRatioTTM | 1.243 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.569 | 0.800 | -1.359 | -1.087 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.309 | -1.500 | 4.85 | -7.28 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.591 | -1.500 | 7.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.701 | 1.000 | 1.644 | 1.644 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.123 | 1.000 | 9.54 | 9.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.197 | 1.000 | -0.0159 | -0.0159 | [0.2 - 2] |
assetTurnoverTTM | 0.556 | 0.800 | 9.63 | 7.70 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.63 | 1.000 | 6.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0503 | 2.50 | -0.355 | -0.828 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.93 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.87 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.243 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.110 | 1.000 | 9.76 | 0 | [0.1 - 0.5] |
Total Score | 4.99 |
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico